

Versameb at Sachs 21st Annual Biotech in Europe Forum

- *Isabel Ferreira speaking on the “Platform Technologies and Novel Therapeutics” Panel*

4 October 2021, Basel, Switzerland: Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces its participation in the [21st Annual Biotech in Europe Forum](#) organized by SACHS Associates taking place virtually 7th-8th October 2021.

Isabel Ferreira, Chief Business Officer of Versameb AG will be participating in a panel discussion titled “Platform Technologies & Novel Therapeutics” taking place at 14.40 CET on 7th October 2021 and chaired by Bibhash Mukhopadhyay, Independent and Stefan Luzi, Partner at Gilde Healthcare Partners. Other panelists include Frauke Hein, Co-Founder & CBO, Adrenomed AG, Lynn Durham, Founder & CEO, STALICLA SA, Mike Romanos, Co-Founder & CEO, Microbiotica Ltd. and Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.

-Ends-

Contact for media enquiries:

Versameb

Dr Klaas Zuideveld, CEO

ir@versameb.com

Optimum Strategic Communications

Mary Clark, Stella Lempidaki, Zoe Bolt

Tel: +44 (0)20 3950 9144

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors with a focus on Renal Cell Carcinoma (RCC) and Head and Neck Cancer (H&N). Versameb is working towards the completion of a first-in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).